Maggiore Amends Zivo Bioscience Stake, Signals Ownership Shift

TL;DR

**Maggiore updated his Zivo Bioscience stake, watch for potential impact.**

AI Summary

Christopher D. Maggiore, an individual, filed an Amendment No. 5 to his Schedule 13D for Zivo Bioscience, Inc. on January 22, 2024, reporting an event that occurred on December 13, 2023. This filing indicates a change in his beneficial ownership of Zivo Bioscience's Common Stock, $0.001 par value. For investors, this matters because it signals a significant shareholder's updated position, which could influence stock perception or future corporate actions.

Why It Matters

Changes in significant shareholder positions can signal confidence or concern, potentially influencing other investors' decisions and the stock's short-term price movement.

Risk Assessment

Risk Level: medium — Changes in major shareholder filings can introduce uncertainty or speculation, leading to moderate stock volatility.

Analyst Insight

An investor should monitor subsequent filings from Christopher D. Maggiore to understand the nature of the change in his beneficial ownership and assess any potential implications for Zivo Bioscience's stock performance or corporate governance.

Key Players & Entities

• Christopher D. Maggiore (person) — reporting person and significant shareholder
• Zivo Bioscience, Inc. (company) — the issuer of the securities
• December 13, 2023 (date) — date of event requiring the filing
• $0.001 (dollar_amount) — par value of common stock

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti
• $38.40 — Person at exercise prices ranging from $38.40 to $57.60, with a weighted average exer
• $57 — exercise prices ranging from $38.40 to $57.60, with a weighted average exercise pr
• $48.00 — th a weighted average exercise price of $48.00. The Reporting Person also owns deriva
• $16.74 — Stock, at exercise prices ranging from $16.74 to $33.00 per share, with a weighted av
• $33.00 — exercise prices ranging from $16.74 to $33.00 per share, with a weighted average exer
• $26.52 — th a weighted average exercise price of $26.52. Other than as reported above with res
• $1.00 — es of Common Stock at purchase price of $1.00 per share, which was reported by the Re
• $1.30 — es of Common Stock at purchase price of $1.30 per share, which was reported by the Re

Filing Documents

• zivo_sc13d.htm (SC 13D) — 60KB
• 0001654954-24-000795.txt ( ) — 61KB

Security and Issuer

Item 1. Security and Issuer This statement on Schedule 13D/A (this "Statement") filed by the Reporting Person relates to the common stock, $0.001 par value (the "Common Stock" or "Securities"), of Zivo Bioscience, Inc., a Nevada corporation the principal executive offices of which are located at 21 East Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304 (the "Company" or "Issuer"). As disclosed in the Company's Current Report on Form 8-K filed October 26, 2023, the Company effected a reverse stock split of its issued and outstanding shares of Common Stock and treasury shares on a 1-for-6 basis, pursuant to which every 6 shares of issued and outstanding Common Stock were converted into one share of Common Stock. A proportionate adjustment was also made to the per share exercise price and number of shares issuable under all of the Company's outstanding stock options and warrants to purchase shares of Common Stock.

Identity and Background

Item 2. Identity and Background (a) Christopher D. Maggiore (b) 4788 Nobles Pond Drive NW, Canton Ohio 44718 (c) Private investor managing a portfolio of businesses and investments (d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) United States

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration Personal funds

Purpose of Transaction

Item 4. Purpose of Transaction The Reporting Person acquired the Securities reported in this Statement for personal investment purposes; Reporting Person currently serves as a director of Issuer. Included in the number of Securities reported as beneficially owned by the Reporting Person are an aggregate of 3,381 shares of Common Stock issuable pursuant to warrants owned by the Reporting Person at exercise prices ranging from $38.40 to $57.60, with a weighted average exercise price of $48.00. The Reporting Person also owns derivative securities of the Company in the form of non-statutory stock options to purchase a total of 14,961 shares of Common Stock, at exercise prices ranging from $16.74 to $33.00 per share, with a weighted average exercise price of $26.52. Other than as reported above with respect to Reporting Person's rights to exercise warrants or non-statutory stock options to acquire shares of Common Stock of the Issuer, the Reporting Person has no current plans or proposals which relate to or would result in: CUSIP No. 98978N 101 SCHEDULE 13D/A Page 4 of 6 (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. (a),(b) The following table sets forth, as of the date of this Statement, the aggregate number and percentage of outstanding Securities which the Reporting Person may be deemed to beneficially own, as well as the number and percentage of Securities as to which the Reporting Person has or will have the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, and shared power to dispose or to direct the disposition. Securities over which the Reporting Person has or will have sole voting and sole dispositive power include (i) 336,816 shares of Common Stock owned by the Reporting Person, (ii) 3,381 shares of Common Stock issuable upon exercise of warrants owned by the Reporting Person, and (iii) 14,961 shares of Common Stock issuable upon exercise of non-statutory stock options held by the Reporting Person. Securities over which the Reporting Person previously reported having shared voting and shared dispositive power related to shares of Common Stock held in the estate of Robert S. McLain and a related trust as to which the Reporting Person was previously a co-trustee but with respect to which Reporting Person had no direct or indirect pecuniary interest. The Reporting Person is no longer a co-trustee of such estate or related trust and therefore no longer has shared voting or dispositive power related to the shares of Common Stock held in the estate. The percentage set forth below is based on 2,748,167 shares of Common Stock outstanding as reported in the Issuer's Current Report on Form 8-K filed on January 17, 2024, plus 3,381 shares of Common Stock issuable upon exercise of all warrants owned by the Reporting Person, plus 14,054 shares of Common Stock issuable upon exercise of all non-statutory stock options held by the Reporting Person. Amount beneficially owned Percent of class % Sole power to vote or to direct the v

Contracts, Arrangements, Understandings, or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings, or Relationships with Respect to Securities of the Issuer Other than the Reporting Person's relationship as a director of the Company and the warrants and non-statutory stock options reported in Item 5 of this Statement, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits. None. CUSIP No. 98978N 101 SCHEDULE 13D/A Page 6 of 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. CHRISTOPHER D. MAGGIORE Date: January 22, 2024 /s/ Christopher D. Maggiore Christopher D. Maggiore

View Full Filing

View this SC 13D filing on SEC EDGAR